We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Blood Cancer UK has renewed its partnership with RareCan, aiming to further enhance RareCan’s patient membership and accelerate the implementation of clinical trials focused on the prevention, diagnosis,
Tagworks Pharmaceuticals has secured a Series A financing round of $65m, with Ysios Capital and Gilde Healthcare leading the investment. Notable participants in the funding round include Novartis
PharmaTher Holdings, a specialised pharmaceutical company with a focus on commercialisation, has formed a collaboration agreement with Vitruvias Therapeutics, a US-based company specialising in generic pharmaceuticals. The collaboration
Surmodics, a provider of healthcare solutions for medical device and in vitro diagnostic technologies, has announced that its SurVeil drug-coated balloon (DCB) has received approval from the US
Merck, internationally recognised as MSD beyond the borders of the US and Canada, has officially finalised the acquisition of Prometheus Biosciences. With this development, Prometheus now operates as
On 11 June 2023, Viva Biotech Holdings Group made an announcement regarding significant developments in its CRO business. Viva Shanghai, the primary entity responsible for Viva Biotech’s CRO
Rosemont Pharmaceuticals (Rosemont) has acquired Lucis Pharma, a specialist pharmaceutical business in the UK, for an undisclosed sum. This acquisition presents exciting opportunities for accelerated growth as it
Astellas Pharma and Cullgen have recently announced a research collaboration accompanied by an exclusive option agreement aimed at discovering and developing innovative protein degraders. The collaboration involves combining
Alentis Therapeutics, a biotechnology company in the clinical stage of development, focusing on therapies for tumours and organ fibrosis associated with Claudin-1 positive (CLDN1+) conditions, recently shared news
Samsung Biologics and Pfizer have unveiled a strategic partnership aimed at facilitating the long-term commercial manufacturing of Pfizer’s diverse range of products. Building upon their initial manufacturing agreement